Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010 (2010), Article ID 891505, 8 pages
http://dx.doi.org/10.1155/2010/891505
Research Article

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

1Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
2Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
3Department of Epidemiology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
4Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands

Received 7 June 2010; Accepted 16 July 2010

Academic Editor: Wmartin Martin Kast

Copyright © 2010 Renee Vermeij et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” Ca: A Cancer Journal for Clinicians. In press. View at Publisher · View at Google Scholar · View at PubMed
  2. C. H. Holschneider and J. S. Berek, “Ovarian cancer: epidemiology, biology, and prognostic factors,” Seminars in Surgical Oncology, vol. 19, no. 1, pp. 3–10, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Bookman, “Standard treatment in advanced ovarian cancer in 2005: the state of the art,” International Journal of Gynecological Cancer, vol. 15, no. 6, pp. 212–220, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. F. Coilinson and G. Jayson, “New therapeutic agents in ovarian cancer,” Current Opinion in Obstetrics and Gynecology, vol. 21, no. 1, pp. 44–53, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. H. T. Khong and N. P. Restifo, “Natural selection of tumor variants in the generation of “tumor escape” phenotypes,” Nature Immunology, vol. 3, no. 11, pp. 999–1005, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. J. H. Kessler and C. J. M. Melief, “Identification of T-cell epitopes for cancer immunotherapy,” Leukemia, vol. 21, no. 9, pp. 1859–1874, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. I. M. Svane, A. E. Pedersen, K. Nikolajsen, and M.-B. Zocca, “Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2,” Vaccine, vol. 26, no. 36, pp. 4716–4724, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. Kuball, M. Schuler, and M. Schuler, “Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man,” Gene Therapy, vol. 9, no. 13, pp. 833–843, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. G. Menon, P. J. K. Kuppen, and P. J. K. Kuppen, “Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients,” Cancer Gene Therapy, vol. 10, no. 7, pp. 509–517, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. C. Chaise, S. L. Buchan, and S. L. Buchan, “DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance,” Blood, vol. 112, no. 7, pp. 2956–2964, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. Tsuruma, Y. Iwayama, and Y. Iwayama, “Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer,” Journal of Translational Medicine, vol. 6, article 24, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. C. S. M. Diefenbach, S. Gnjatic, and S. Gnjatic, “Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission,” Clinical Cancer Research, vol. 14, no. 9, pp. 2740–2748, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. K.A. Chianese-Bullock, S. T. Lewis, N. E. Sherman, J. D. Shannon, and C. L. Slingluff Jr., “Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies,” Vaccine, vol. 27, no. 11, pp. 1764–1770, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. M. Straughn Jr., D. R. Shaw, and D. R. Shaw, “Expression of sperm protein 17 (Sp17) in ovarian cancer,” International Journal of Cancer, vol. 108, no. 6, pp. 805–811, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. M. Kirkwood, S. Lee, and S. Lee, “Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFIN-α2b in advanced metastatic melanoma: eastern cooperative oncology group phase II trial E1696,” Clinical Cancer Research, vol. 15, no. 4, pp. 1443–1451, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. H. W. Nijman, A. Lambeck, S. H. van der Burg, A. G. J. van der Zee, and T. Daemen, “Immunologic aspect of ovarian cancer and p53 as tumor antigen,” Journal of Translational Medicine, vol. 3, article 34, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. P. de Graeff, J. Hall, and J. Hall, “Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies,” British Journal of Cancer, vol. 95, no. 5, pp. 627–633, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. Lambeck, N. Leffers, and N. Leffers, “P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy,” International Journal of Cancer, vol. 121, no. 3, pp. 606–614, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. Chiriva-Internati, F. Grizzi, and F. Grizzi, “A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17,” Journal of Immunological Methods, vol. 321, no. 1-2, pp. 86–93, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Nakazato, T. Kanuma, T. Tamura, L. S. Faried, H. Aoki, and T. Minegishi, “Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer,” International Journal of Gynecological Cancer, vol. 17, no. 2, pp. 426–432, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. Y. Oka, A. Tsuboi, Y. Oji, I. Kawase, and H. Sugiyama, “WT1 peptide vaccine for the treatment of cancer,” Current Opinion in Immunology, vol. 20, no. 2, pp. 211–220, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. G. Li, Y. Zeng, and Y. Zeng, “Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro,” Clinical and Experimental Immunology, vol. 148, no. 1, pp. 136–145, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. H. J. Stauss, S. Thomas, and S. Thomas, “WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells,” Blood Cells, Molecules, and Diseases, vol. 40, no. 1, pp. 113–116, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. C. Cohen, C. M. Lohmann, G. Cotsonis, D. Lawson, and R. Santoianni, “Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis,” Modern Pathology, vol. 16, no. 6, pp. 574–583, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. L. Sui, Y. Dong, M. Ohno, Y. Watanabe, K. Sugimoto, and M. Tokuda, “Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors,” International Journal of Oncology, vol. 21, no. 2, pp. 315–320, 2002. View at Google Scholar · View at Scopus
  26. N. Zaffaroni, M. Pennati, and M. Pennati, “Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer,” Cellular and Molecular Life Sciences, vol. 59, no. 8, pp. 1406–1412, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Matsuzaki, F. Qian, and F. Qian, “Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1,” Cancer Immunology, Immunotherapy, vol. 57, no. 8, pp. 1185–1195, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. Y.-T. Chen, M. Hsu, and M. Hsu, “Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer,” International Journal of Cancer, vol. 124, no. 12, pp. 2893–2898, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. N. Leffers, M. J. M. Gooden, and M. J. M. Gooden, “Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer,” Gynecologic Oncology, vol. 113, no. 2, pp. 256–263, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. N. Leffers, A. J. A. Lambeck, P. de Graeff, A. Y. Bijlsma, T. Daemen, A. G. J. van der Zee, and H. W. Nijman, “Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation,” Gynecologic Oncology, vol. 110, no. 3, pp. 365–373, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. “Cancer Committee of the International Federation of Gynaecology and Obstetrics. Staging announcement: FIGO Cancer Committee,” Gynecological Oncology, vol. 25, pp. 383–385, 1986.
  32. R. E. Scully, “Histological typing of ovarian tumours,” in World Health Organisation. International Histological Classification of Tumours, pp. 11–19, Springer, Berlin, Germany, 2004. View at Google Scholar
  33. F. Grizzi, P. Gaetani, and P. Gaetani, “Sperm protein 17 is expressed in human nervous system tumours,” BMC Cancer, vol. 6, article 23, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. G. Acs, T. Pasha, and P. J. Zhang, “WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium,” International Journal of Gynecological Pathology, vol. 23, no. 2, pp. 110–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Shimizu, T. Toki, Y. Takagi, I. Konishi, and S. Fujii, “Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors,” International Journal of Gynecological Pathology, vol. 19, no. 2, pp. 158–163, 2000. View at Google Scholar · View at Scopus
  36. L. Kleinberg, V. A. Florenes, I. Silins, K. Haug, C. G. Trope, J. M. Nesland, and B. Davidson, “Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma,” Cancer, vol. 109, no. 2, pp. 228–238, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. G. Ferrandina, F. Legge, and F. Legge, “Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters,” British Journal of Cancer, vol. 92, no. 2, pp. 271–277, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. K. Odunsi, A. A. Jungbluth, and A. A. Jungbluth, “NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer,” Cancer Research, vol. 63, no. 18, pp. 6076–6083, 2003. View at Google Scholar · View at Scopus
  39. N. M. T. Jawhar, “Tissue microarray: a rapidly evolving diagnostic and research tool,” Annals of Saudi Medicine, vol. 29, no. 2, pp. 123–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Chiriva-Internati, Z. Wang, E. Salati, P. Timmins, and S. H. Lim, “Tumor vaccine for ovarian carcinoma targeting sperm protein 17,” Cancer, vol. 94, no. 9, pp. 2447–2453, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. V. Barbolina, B. P. Adley, L. D. Shea, and M. S. Stack, “Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion,” Cancer, vol. 112, no. 7, pp. 1632–1641, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. K. Milne, R. O. Barnes, and R. O. Barnes, “Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer,” PLoS ONE, vol. 3, no. 10, article e3409, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick, “Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms,” Clinical Cancer Research, vol. 9, no. 17, pp. 6453–6460, 2003. View at Google Scholar · View at Scopus
  44. A. Woloszynska-Read, P. Mhawech-Fauceglia, J. Yu, K. Odunsi, and A. R. Karpf, “Intertumor and intratumor NY-ESO-1 expression heterogeneity Is associated With promoter-specific and global DNA methylation status in ovarian cancer,” Clinical Cancer Research, vol. 14, no. 11, pp. 3283–3290, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. J. Scanlan, A. O. Gure, A. A. Jungbluth, L. J. Old, and Y.-T. Chen, “Cancer/testis antigens: an expanding family of targets for cancer immunotherapy,” Immunological Reviews, vol. 188, pp. 22–32, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. P. de Graeff, A. P. G. Crijns, and A. P. G. Crijns, “The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer,” British Journal of Cancer, vol. 99, no. 2, pp. 341–349, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. M. V. Seiden, H. A. Burris, and H. A. Burris, “A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies,” Gynecologic Oncology, vol. 104, no. 3, pp. 727–731, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. C.-H. Lee, D. G. Huntsman, and D. G. Huntsman, “Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma,” International Journal of Gynecological Pathology, vol. 24, no. 2, pp. 147–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. D. E. Milenic, K. J. Wong, K. E. Baidoo, G. L. Ray, K. Garmestani, M. Williams, and M. W. Brechbiel, “Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications,” Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 5, pp. 619–631, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. E. Horak, F. Hartmann, and F. Hartmann, “Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1,” Journal of Nuclear Medicine, vol. 38, no. 12, pp. 1944–1950, 1997. View at Google Scholar · View at Scopus
  51. I. M. Svane, A. E. Pedersen, and A. E. Pedersen, “Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study,” Cancer Immunology, Immunotherapy, vol. 53, no. 7, pp. 633–641, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. K. Odunsi, F. Qian, and F. Qian, “Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 31, pp. 12837–12842, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. N. Leffers, A. J. A. Lambeck, and A. J. A. Lambeck, “Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial,” International Journal of Cancer, vol. 125, no. 9, pp. 2104–2113, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. J. Galea-Lauri, J. W. Wells, D. Darling, P. Harrison, and F. Farzaneh, “Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination,” Cancer Immunology, Immunotherapy, vol. 53, no. 11, pp. 963–977, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. R. R. Caspi, “Immunotherapy of autoimmunity and cancer: the penalty for success,” Nature Reviews Immunology, vol. 8, no. 12, pp. 970–976, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. J. M. Kirkwood, A. A. Tarhini, M. C. Panelli, S. J. Moschos, H. M. Zarour, L. H. Butterfield, and H. J. Gogas, “Next generation of immunotherapy for melanoma,” Journal of Clinical Oncology, vol. 26, no. 20, pp. 3445–3455, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. P. Hwu and R. S. Freedman, “The immunotherapy of patients with ovarian cancer,” Journal of Immunotherapy, vol. 25, no. 3, pp. 189–201, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. A. L. Glazyrin, J. Kan-Mitchell, and M. S. Mitchell, “Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells,” Cancer Immunology, Immunotherapy, vol. 52, no. 3, pp. 171–178, 2003. View at Google Scholar · View at Scopus
  59. C.-F. Hung, T. C. Wu, A. Monie, and R. Roden, “Antigen-specific immunotherapy of cervical and ovarian cancer,” Immunological Reviews, vol. 222, no. 1, pp. 43–69, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. C. J. Kim, S. Dessureault, D. Gabrilovich, D. S. Reintgen, and C. L. Slingluff Jr., “Immunotherapy for melanoma,” Cancer Control, vol. 9, no. 1, pp. 22–30, 2002. View at Google Scholar · View at Scopus
  61. M. J. Cannon, A. D. Santin, and T. J. O'Brien, “Immunological treatment of ovarian cancer,” Current Opinion in Obstetrics and Gynecology, vol. 16, no. 1, pp. 87–92, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. G. G. Kenter, M. J. P. Welters, and M. J. P. Welters, “Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity,” Clinical Cancer Research, vol. 14, no. 1, pp. 169–177, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. M. J. Palmowski, E. M.-L. Choi, and E. M.-L. Choi, “Competition between CTL narrows the immune response induced by prime-boost vaccination protocols,” Journal of Immunology, vol. 168, no. 9, pp. 4391–4398, 2002. View at Google Scholar · View at Scopus
  64. N. N. Hunder, H. Wallen, and H. Wallen, “Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2698–2703, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. C. Doehn, N. Esser, and N. Esser, “Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma,” European Urology, vol. 56, no. 1, pp. 123–133, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. Y. Nie, G.-Y. Yang, and G.-Y. Yang, “DNA hypermethylation is a mechanism for loss of expression of HLA class I genes in human esophageal squamous cell carcinomas,” Carcinogenesis, vol. 22, no. 10, pp. 1615–1623, 2001. View at Google Scholar · View at Scopus
  67. C. Sers, R. Kuner, and R. Kuner, “Down-regulation of HLA class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells,” International Journal of Cancer, vol. 125, no. 7, pp. 1626–1639, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. Serrano, S. Tanzarella, I. Lionello, R. Mendez, C. Traversari, F. Ruiz-Cabello, and F. Garrido, “Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment,” International Journal of Cancer, vol. 94, no. 2, pp. 243–251, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus